Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Revance Therapeutics, Inc.
Develops both topical and longer lasting injectable formulations of Botox
Newark, CA
NASDAQ: RVNC
Contact:
Ron Eastman
Formerly Known As: Essentia BioSystems Inc.
IPO
Exit date: February 06, 2014
Related News
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration in Largest-Ever Aesthetic Neuromodu
Revance Announces China Market License Agreement with Fosun Pharma for RT002
Revance’s RT002 Meets Primary and Secondary Endpoints, Achieves 6-Month Duration in Phase 3 Trials
Revance Appoints Mark Foley to its Board of Directors
Revance Announces Positive Results in RT002 Injectable Phase 2 Cervical Dystonia Trial
Revance Reports Positive Six-Month Duration in BELMONT Study
Revance Therapeutics Announces Publication of Positive Results from RT002 Phase 1/2 Study
Revance Therapeutics Added to NASDAQ Biotechnology Index
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study Glabellar Frown Lines
Revance Therapeutics Soars in Debut, While Egalet and Eleven Open Quietly
Revance Therapeutics Regains All Worldwide Rights to its Botulinum Toxin Products
Revance Announces $45M Financing